COMPARISON OF STNFR55 IGG WITH ORAL METHOTREXATE IN ACTIVE RHEUMATOID ARTHRITIS

Ro 45-2081是一种重组分子， 人55 KD TNF α受体的胞外结构域和 免疫球蛋白IgG重链序列 它被设计成具有更长的 体内半衰期和更高的TNF中和能力比天然的 TNF抑制剂。 以前的研究已经在 类风湿性关节炎的患者，并已证明saltingeffect。 本研究将采用皮下给药途径 单独给药或与甲氨蝶呤联合给药， 类风湿性关节炎的临床表现和功能表现 12周期间。

Ro 45-2081 is a recombinent molecule that consists of the complete extracellular domain of the human 55 KD TNF alpha receptor and an immunoglobulin IgG heavy chain sequence. It is designed to have a longer in vivo half-life and higher TNF neutralizing capability than a natural TNF inhibitor. Previous studies have utilized intravenous infusion in patients with rheumatoid arthritis and have demonstrated salutory effects. The current study will utilize a subcutaneous route of administration either given alone or in combination with methotrexate and will evaluate the clinical and functional manifestations of rheumatoid arthritis over a 12 week period.